Opinion

Video

Collaborating with Other Care Providers to Optimize Outcomes for Patients Receiving Bispecifics

Author(s):

Ryan Haumschild, PharmD, MS, MBA,Ke Ning, MD

The expert panel explores the importance of communication and collaboration among care providers when patients with multiple myeloma who are receiving treatment with bispecific antibodies navigate transitions of care to and from various healthcare settings.

Related Videos
3 KOLs are featured in this series.
3 KOLs are featured in this series.
3 KOLs are featured in this series.
3 KOLs are featured in this series.
3 KOLs are featured in this series.
3 KOLs are featured in this series.
3 KOLs are featured in this series.
3 KOLs are featured in this series.
3 KOLs are featured in this series.
3 KOLs are featured in this series.
Related Content
Outpatient Transplant and CAR T-Cell Therapy: A Paradigm Shift in Care Delivery
November 19th 2024

Outpatient Transplant and CAR T-Cell Therapy: A Paradigm Shift in Care Delivery

Alana Hippensteele, Managing Editor
Pharmacy Focus: Oncology Edition
April 17th 2023

Pharmacy Focus: Oncology Edition - Consider Treatment Sequences Carefully in Myeloma

Multiple myeloma cells | Image Credit: © Сергей Косилко - stock.adobe.com
November 11th 2024

Johnson & Johnson Seeks FDA Approval of Daratumumab for Smoldering Multiple Myeloma

Alexandra Gerlach, Associate Editor
Image Credit: © CHA - stock.adobe.com
November 6th 2024

Bone Marrow Adipocytes May Offer Early Detection of MGUS Progression to Multiple Myeloma

Alexandra Gerlach, Associate Editor
Image Credit: © Сергей Косилко - stock.adobe.com
November 1st 2024

Carfilzomib, Lenalidomide, and Dexamethasone: A Curative Approach for Smoldering Multiple Myeloma

Alexandra Gerlach, Associate Editor
Biliary tract cancer -- Image credit: Thipphaphone | stock.adobe.com
October 30th 2024

Emerging Therapies and Precision Medicine Offer Promising Results in Hepatocellular Carcinoma and Biliary Tract Cancer

Gabriela Aponte-Melendez, PharmD Nicole Bentivegna, PharmD, BCOP